1296 related articles for article (PubMed ID: 31265100)
1. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
Berenbaum F; Blanco FJ; Guermazi A; Miki K; Yamabe T; Viktrup L; Junor R; Carey W; Brown MT; West CR; Verburg KM
Ann Rheum Dis; 2020 Jun; 79(6):800-810. PubMed ID: 32234715
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Safety and Efficacy of Subcutaneous Tanezumab Versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial.
Hochberg MC; Carrino JA; Schnitzer TJ; Guermazi A; Walsh DA; White A; Nakajo S; Fountaine RJ; Hickman A; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
Arthritis Rheumatol; 2021 Jul; 73(7):1167-1177. PubMed ID: 33538113
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.
Schnitzer TJ; Ekman EF; Spierings EL; Greenberg HS; Smith MD; Brown MT; West CR; Verburg KM
Ann Rheum Dis; 2015 Jun; 74(6):1202-11. PubMed ID: 24625625
[TBL] [Abstract][Full Text] [Related]
5. Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study.
Schnitzer TJ; Khan A; Bessette L; Davignon I; Brown MT; Pixton G; Prucka WR; Tive L; Viktrup L; West CR
Semin Arthritis Rheum; 2020 Jun; 50(3):387-393. PubMed ID: 32252976
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Dakin P; DiMartino SJ; Gao H; Maloney J; Kivitz AJ; Schnitzer TJ; Stahl N; Yancopoulos GD; Geba GP
Arthritis Rheumatol; 2019 Nov; 71(11):1824-1834. PubMed ID: 31207169
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen.
Ekman EF; Gimbel JS; Bello AE; Smith MD; Keller DS; Annis KM; Brown MT; West CR; Verburg KM
J Rheumatol; 2014 Nov; 41(11):2249-59. PubMed ID: 25274899
[TBL] [Abstract][Full Text] [Related]
9. Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.
Neogi T; Hunter DJ; Churchill M; Shirinsky I; White A; Guermazi A; Omata M; Fountaine RJ; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
Arthritis Res Ther; 2022 Mar; 24(1):78. PubMed ID: 35351194
[TBL] [Abstract][Full Text] [Related]
10. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.
Brown MT; Murphy FT; Radin DM; Davignon I; Smith MD; West CR
Arthritis Rheum; 2013 Jul; 65(7):1795-803. PubMed ID: 23553790
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials.
Chen J; Li J; Li R; Wang H; Yang J; Xu J; Zha Z
Pain Med; 2017 Feb; 18(2):374-385. PubMed ID: 28034979
[TBL] [Abstract][Full Text] [Related]
12. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee.
Spierings ELH; Fidelholtz J; Wolfram G; Smith MD; Brown MT; West CR
Pain; 2013 Sep; 154(9):1603-1612. PubMed ID: 23707270
[TBL] [Abstract][Full Text] [Related]
13. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial.
Brown MT; Murphy FT; Radin DM; Davignon I; Smith MD; West CR
J Pain; 2012 Aug; 13(8):790-8. PubMed ID: 22784777
[TBL] [Abstract][Full Text] [Related]
14. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
Kivitz A; Ma C; Ahdieh H; Galer BS
Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
Berenbaum F; Langford R; Perrot S; Miki K; Blanco FJ; Yamabe T; Isogawa N; Junor R; Carey W; Viktrup L; West CR; Brown MT; Verburg KM
Eur J Pain; 2021 Aug; 25(7):1525-1539. PubMed ID: 33728717
[TBL] [Abstract][Full Text] [Related]
16. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study.
Nagashima H; Suzuki M; Araki S; Yamabe T; Muto C;
Osteoarthritis Cartilage; 2011 Dec; 19(12):1405-12. PubMed ID: 22004765
[TBL] [Abstract][Full Text] [Related]
17. Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials.
Berenbaum F; Schnitzer T; Kivitz A; Viktrup L; Johnston E; Yang R; Whalen E; Tive L; Semel D
Int J Clin Pract; 2021 Dec; 75(12):e14975. PubMed ID: 34626502
[TBL] [Abstract][Full Text] [Related]
18. Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial.
Hochberg MC; Guermazi A; Guehring H; Aydemir A; Wax S; Fleuranceau-Morel P; Reinstrup Bihlet A; Byrjalsen I; Ragnar Andersen J; Eckstein F
JAMA; 2019 Oct; 322(14):1360-1370. PubMed ID: 31593273
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled phase III trials.
Fan ZR; Ma JX; Wang Y; Chen HT; Lang S; Ma XL
Clin Rheumatol; 2021 Jun; 40(6):2155-2165. PubMed ID: 33159281
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies.
Kelly KM; Sanga P; Zaki N; Wang S; Haeussler J; Louie J; Thipphawong J
Curr Med Res Opin; 2019 Dec; 35(12):2117-2127. PubMed ID: 31387410
[No Abstract] [Full Text] [Related]
[Next] [New Search]
